James McCullough of RenalytixAI

February 1, 2021

BioUtah president & CEO Kelvyn Cullimore interviews RenalytixAI CEO James McCullough to discuss the growth and innovations of RenalytixAI, a diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs. Topics discussed include:

• Kidney diseases prognostics
• Alternate means of funding a life sciences company
• Life sciences companies locating in Utah
• Much more

James McCullough Bio:

James McCullough has served as our co-founder and Chief Executive Officer since our inception. Mr. McCullough has leadership experience building emerging technology companies in both the public and private sectors with specific expertise in the life-sciences industry. From 2008 to 2014, he served as chief executive officer of Exosome Diagnostics Inc., a venture backed personalized medicine company developing non-invasive liquid biopsy diagnostics in cancer that was acquired by Bio-Techne Corporation in 2018. Since 2014, Mr. McCullough has also served as a managing partner of Renwick Capital, LLC, a management consulting firm specializing in assisting emerging healthcare technology companies with strategic planning and business execution. He received his B.A. from Boston University and an MBA from Columbia Business School.